Function of Immune Checkpoints in IgG4–Related Disease with Lacrimal Gland Involvement: Clinical Features, Serum IgG4 Level, Immunohistochemical Landscape, and Treatment Responses
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073021 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dong Hyuck Bae und 5 weiteren Autor:innen. Beteiligte Einrichtung: R&D Institute, Organoidsciences Ltd., Seongnam 13488, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Lacrimal Apparatus, Immunoglobulin G, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Trade, Industry & Energy (MOTIE, Korea), Ministry of Trade, Industry & Energy (MOTIE, Korea).
Abstract (Originalsprache)
IgG4–related disease (IgG4–RD) is an autoimmune condition marked by IgG4–positive plasma cell infiltration, causing inflammation, fibrosis, and tumor–like lesions, especially in the lacrimal gland (LG). Current diagnostic criteria, based primarily on serum IgG4 levels, face limitations in predicting clinical outcomes and treatment responses. To address this, we conducted a multiplex immaunohistochemical analysis of LG tissues to assess immune checkpoint interactions and immune cell distribution in relation to mass size, fibrosis, and treatment response. Our findings revealed that PD–L1 (Programmed Death–Ligand 1), an immune checkpoint molecule, plays a key role in shaping an immunosuppressive environment that varies by clinical group. In non–responsive patients, increased co–expression of PD–L1 and CD11c+ dendritic cells (DCs) suggested a link to treatment resistance. Spatial analysis highlighted more active immune responses in non–fibrotic areas, while fibrotic regions exhibited stabilized immune interactions driven by PD–L1 expression. These results indicate that PD–L1 contributes to immune regulation and disease progression in IgG4–RD and emphasize its potential as a therapeutic target. This study provides new insights into the immunological landscape of IgG4–RD and paves the way for the development of personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&D Institute, Organoidsciences Ltd., Seongnam 13488, Gyeonggi-do, Republic of Korea.
- Department of Microbiology, CHA University School of Medicine, Seongnam 13488, Gyeonggi-do, Republic of Korea.
- CHA Organoid Research Center, CHA University, Seongnam 13488, Gyeonggi-do, Republic of Korea.
- Department of Ophthalmology, Bundang CHA Medical Center, CHA University, Seongnam 13496, Gyeonggi-do, Republic of Korea.
- Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Gyeonggi-do, Republic of Korea.
- Department of Pathology, Bundang CHA Medical Center, CHA University, Seongnam 13496, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Gwang Il Kim, Helen Lew
Förderung
- the Ministry of Trade, Industry & Energy (MOTIE, Korea)
- Ministry of Trade, Industry & Energy (MOTIE, Korea)
Zitieren
APA
Bae, D. H., Kim, Y. R., Yang, W., Kim, G. I., Lew, H., & Yoo, J. (2025). Function of Immune Checkpoints in IgG4–Related Disease with Lacrimal Gland Involvement: Clinical Features, Serum IgG4 Level, Immunohistochemical Landscape, and Treatment Responses. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073021
Vancouver
Bae DH, Kim YR, Yang W, Kim GI, Lew H, Yoo J. Function of Immune Checkpoints in IgG4–Related Disease with Lacrimal Gland Involvement: Clinical Features, Serum IgG4 Level, Immunohistochemical Landscape, and Treatment Responses. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073021
BibTeX
@article{Bae2025,
author = {Bae, Dong Hyuck and Kim, Yoo Ri and Yang, WooKyeom and Kim, Gwang Il and Lew, Helen and Yoo, Jongman},
title = {Function of Immune Checkpoints in IgG4–Related Disease with Lacrimal Gland Involvement: Clinical Features, Serum IgG4 Level, Immunohistochemical Landscape, and Treatment Responses},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073021}
}
EUVIMED